BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosisReport as inadecuate




BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis - Download this document for free, or read online. Document in PDF available to download.

Cancer Cell International

, 10:21

First Online: 29 June 2010Received: 02 February 2010Accepted: 29 June 2010

Abstract

BackgroundIntravesical immunotherapy with Mycobacterium bovis bacillus Calmette-Guérin has been established as the most effective adjuvant treatment for high risk non-muscle-invasive bladder cancer NMIBC. We investigated the differences between the S4-Jena BCG strain and commercially available BCG strains. We tested the genotypic varieties between S4-Jena and other BCG strains and analysed the effect of the BCG strains TICE and S4-Jena on two bladder cancer cell lines.

ResultsIn contrast to commercially available BCG strains the S4-Jena strain shows genotypic differences. Spoligotyping verifies the S4-Jena strain as a BCG strain. Infection with viable S4-Jena or TICE decreased proliferation in the T24 cell line. Additionally, hallmarks of apoptosis were detectable. In contrast, Cal29 cells showed only a slightly decreased proliferation with TICE. Cal29 cells infected with S4-Jena, though, showed a significantly decreased proliferation in contrast to TICE. Concordantly with these results, infection with TICE had no effect on the morphology and hallmarks of apoptosis of Cal29 cells. However, S4-Jena strain led to clearly visible morphological changes and caspases 3-7 activation and PS flip.

ConclusionsS4-Jena strain has a direct influence on bladder cancer cell lines as shown by inhibition of cell proliferation and induction of apoptosis. The data implicate that the T24 cells are responder for S4-Jena and TICE BCG. However, the Cal29 cells are only responder for S4-Jena and they are non-responder for TICE BCG. S4-Jena strain may represent an effective therapeutic agent for NMIBC.

AbbreviationsBCGMycobacterium bovis bacillus Calmette-Guérin

LSMlaser scanning microscopy

NMIBCnon-muscle-invasive bladder cancer

PFGEpulsed field gel electrophoresis

PSphosphatidylserine

Electronic supplementary materialThe online version of this article doi:10.1186-1475-2867-10-21 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Katja Schwarzer - Martin Foerster - Thomas Steiner - Inge-Marie Hermann - Eberhard Straube

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents